Clinical trial NCT07005063: Rotator Cuff Tendon Repair With FiberLocker System Patch Augmentation
Official title: Rotator Cuff Tendon Repair With FiberLocker System Patch Augmentation: A Prospective, Single-Arm, Non-Randomized, Pilot Study
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Rotator Cuff Tear
Rotator Cuff Injury
Rotator Cuff Rupture
Keywords: Rotator cuff tear
Rotator cuff repair
Augmentation
Reinforcement
Mechanical augmentation
Lead sponsor: ZuriMED Technologies AG
Sponsor class: INDUSTRY
First posted: 2025-06-04
Enrollment: 50
Sex: ALL
Minimum age (years): 40
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The overall objective of this clinical investigation is to assess the safety and efficacy of full-thickness arthroscopic rotator cuff repairs augmented with the FiberLocker System for the subjects. The primary outcome of the investigation is to assess the safety after full-thickness arthroscopic rotator cuff repairs augmented with the FiberLocker System in terms of postoperative adverse events through the 12-month follow-up. Main secondary outcomes include measures of efficacy and clinical performance evaluated at 6-week, 4.5-month, and 12-month follow-ups including retear rate assessed using MRI and different functional performance scores.


Eligibility criteria: Inclusion Criteria:

1. Subject requires surgical treatment of a full-thickness rotator cuff tear, according to Balgrist standard procedure
2. Full-thickness tear of the supraspinatus or combined infraspinatus and supraspinatus
3. The rotator cuff tear is of traumatic origin.
4. Subject is ≥ 40 years of age \& ≤ 65 years of age.
5. Primary rotator cuff repair
6. Informed Consent signed by the subject
7. Pre-operative MRI performed

Exclusion Criteria:

1. Vulnerable subjects (as defined in ISO 14155)
2. Subjects who do not have the power of judgement or are unable to fully understand all aspects of the investigation that are relevant to the decision to participate
3. Participation in another investigation with an investigational drug or another MD within the 30 days preceding and during the present investigation,
4. Previous enrolment into the current investigation,
5. Enrolment of the PI, his/her family members, employees and other dependent persons,
6. Inability to follow the procedures of the investigation, or known or suspected non-compliance, e.g. due to language problems, psychological disorders, dementia, drug or alcohol abuse, etc. of the subject
7. Active smoker
8. History of claustrophobia that would prevent an MRI of the index shoulder
9. Presence of an implanted metallic device or other implants that would contraindicate acquisition or inhibit radiologist review of an MRI of the index shoulder
10. Pregnant or planning to become pregnant during the study period
11. Breast feeding women
12. Subject has conditions or circumstances that would interfere with study requirements.
13. Contraindications and limitations of the MD as described in the IFUs.
14. Partial rotator cuff tears
15. History or known allergy or intolerance to polyester
16. Complete full-thickness subscapularis tears greater than the superior 1/3 of the tendon, with Lafosse grade 3 or greater
17. Massive rotator cuff tears, tear size equal to or greater than 4 cm in the anterior-posterior dimension or irreparable rotator cuff tear
18. Limited space or exposure for implant delivery
19. Structural or pathological condition of the bone or soft tissue that could impair healing.
20. Intraoperative rotator cuff tear characteristics differ from preoperatively expected characteristics and fulfil one of the abovementioned criteria
21. Fatty infiltration of the index shoulder rotator cuff muscle \> Goutallier Score 2
22. Corticosteroid injection in the operative shoulder within 6 weeks of operation
23. Subject shows frozen shoulder/adhesive capsulitis at day of surgery
24. Cases of moderate to severe osteoarthritis
25. Patients with inflammatory disease or auto-immune based joint diseases (e.g., rheumatoid arthritis, systemic lupus erythematosus, arthropathy)
26. Subjects with diabetes type I or II
27. The subject currently has an acute infection in the area surrounding the surgical site
28. Evidence of active infection, osteomyelitis, sepsis or distant infection which could spread to the index joint.
29. Any comorbidity or condition that renders the patient a poor surgical candidate as determined by the Investigator.

Primary outcomes:
measure: Total Number of Adverse Events (AEs)
timeFrame: Surgery to 12-month follow-up
measure: Total Number of Serious Adverse Events (SAEs)
timeFrame: Surgery to 12-month follow-up
measure: Number of AE related to Device
timeFrame: Surgery to 12-month follow-up
measure: Number of SAE related to Device
timeFrame: Surgery to 12-month follow-up
measure: Number of AE related to Procedure
timeFrame: Surgery to 12-month follow-up
measure: Number of SAE related to Procedure
timeFrame: Surgery to 12-month follow-up
Secondary outcomes:
measure: Retear Rate
timeFrame: 6-week, 4.5-month and 12-month follow-up
measure: Constant-Murley Score
timeFrame: Baseline and 12-month follow-up
measure: Visual Analog Scale for Pain (VAS)
timeFrame: Baseline, 2-week, 4.5-month and 12-month follow-up
measure: Subjective Shoulder Value (SSV) Score
timeFrame: Baseline, 4.5-month and 12-month follow-up
measure: EQ-5D-5L survey
timeFrame: Baseline, 4.5-month and 12-month follow-up
measure: American Shoulder and Elbow Society (ASES) score
timeFrame: Baseline, 4.5-month and 12-month follow-up
measure: Sugaya Classification
timeFrame: 6-week, 4.5-month and 12-month follow-up
measure: Goutallier Classification
timeFrame: Baseline, 6-week, 4.5-month and 12-month follow-up
measure: Tendon Thickness
timeFrame: Baseline, 6-week, 4.5-month and 12-month follow-up
measure: Fat Fraction of Muscle
timeFrame: Baseline, 6-week, 4.5-month and 12-month follow-up
Other outcomes:
Locations:
Study officials:
References: